Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years or older~* Histologically confirmed and documented recurrent ovarian, fallopian tube, and peritoneal cancer.~* Platinum resistant disease, defined as progression within ≤ 6 months from completion of most recent regimen and calculated from the date of the last administered dose of platinum therapy~* Must have available archived tumor tissue OR if archived tissue is not available, willing to provide a fresh tumor biopsy~* Must have radiologic imaging with a computerized tomography (CT) scan or magnetic resonance imaging (MRI) within 4 weeks of first dose of study drug~* Received at least 1 but not more than 3 therapy regimens, not including maintenance or adjuvant therapy~* Must have ovarian cancer that is measurable according to RECIST 1.1~* ECOG performance status of 0-1~* Normal gastrointestinal (GI), bone marrow, liver and kidney function~* At least 28 days between termination of prior anti-cancer or hormonal therapy and administration of AVB-S6-500~Exclusion Criteria:~* Primary platinum-refractory disease (defined as progression during the first platinum regimen or within 4 weeks of completion of the first platinum regimen)~* Currently being treated with concurrent anti-cancer therapy or any other interventional treatment or trial~* Received prior therapy with Pac or PLD in the recurrent setting, depending on physician-chosen chemotherapy for this study~* Significant cardiac disease history~* Has other prior or concurrent malignancy within the past 5 years except adequately treated basal cell skin cancer or carcinoma in situ of the cervix~* Symptomatic CNS metastasis or metastases~* Serious active infection requiring IV antibiotics and/or hospitalization at study entry~* Has known previous or current human immune deficiency (HIV) syndrome, hepatitis B, or hepatitis C~* Has had paracentesis for ascites within 3 months

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Phase 1b: AVB-S6-500+PLD (Type: EXPERIMENTAL): None
- Phase 1b: AVB-S6-500+Pac (Type: EXPERIMENTAL): None
- Phase 2: AVB-S6-500+PLD (Type: EXPERIMENTAL): None
- Phase 2: AVB-S6-500+Pac (Type: EXPERIMENTAL): None
- Phase 2: Placebo+PLD (Type: ACTIVE_COMPARATOR): None
- Phase 2: Placebo+Pac (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).